ALSO NOTED: Generic Plavix grabs big market share; Medarex to collaborate on antibodies; and much more...

> The generic version of Plavix has already claimed slightly more than 60 percent of the total market for the drug and 74 percent of all new prescriptions. In court testimony yesterday a financial expert hired by Apotex says that if the generic drug maker loses its fight to continue selling the drug, it would cost the company $4 billion. Report [1]

> Medarex and Germany's GenPat77 Pharmacogenetics will collaborate on developing new human antibody products. Report [2]

> The popular acne drug Roaccutane, made by Roche, has been linked to high cholesterol levels and damage to the liver. Report [3]

> GenVec announced plans for the first human therapeutic clinical trial involving the company's adenoviral-vector technology used in an HIV vaccine candidate. Release [4]

> GlaxoSmithKline is developing a research project into gastrointestinal diseases in collaboration with Alimentary Pharmabiotic Centre in Ireland. Report [5]

> Myriad Genetics has closed enrollment for its Phase III trial of the Alzheimer's drug Flurizan. Report [6]

> Nabi Biopharmaceuticals has agreed to pay a schedule of milestones payments to ProMetic Life Sciences for the use of ProMetic's Mimetic Ligands technology in the manufacturing of selected plasma-derived hyperimmune products. Release [7]

And Finally… Cases of potentially lethal M.R.S.A. continue to grow around the country. Article [8]